FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385702500> ?p ?o ?g. }

• W4385702500 endingPage "e002748c" @default.
• W4385702500 startingPage "e002748c" @default.
• W4385702500 abstract "Topic: 22. Stem cell transplantation - Clinical Background: Maintenance therapy is considered standard of care after upfront autologous hematopoietic stem cell transplantation (auto-HCT) for patients with newly diagnosed multiple myeloma (MM). However, there is paucity of data on the use of maintenance after a salvage auto-HCT, whether first or second. Aims: We designed a clinical trial for relapsed MM patients who underwent salvage auto-HCT after disease relapse to receive post-transplant maintenance with daratumumab (dara), with the addition of pomalidomide (pom) in a later amendment. Methods: We hypothesized that maintenance therapy with dara +/- pom will improve the progression-free survival (PFS) after a salvage auto-HCT. Patients with prior exposure to dara or pom were included, but patients refractory to either drug were excluded. The trial was planned to enroll a total of 56 patients. Patients received dara SQ weekly for weeks 1–8, every 2 weeks for weeks 9–24, and monthly from week 25 until progression. Pom was given at 2 mg PO from day 1–21 every 28 days. Patients received herpes zoster prophylaxis for the duration of the trial. The primary outcome of this phase II trial was PFS. Disease response was assessed according to the International Myeloma Working Group (IMWG) uniform response criteria. Minimal residual disease (MRD) was measured by multiparametric flow cytometry (10-5) in the bone marrow at day 90–180 after transplant. Results: The trial was terminated due to poor accrual after 13/56 patients were enrolled between May 2019 and August 2022. Median age at salvage auto-HCT was 64 (range: 43–76) years, and 7 patients (54%) were male. Median prior lines of treatment was 2 (range: 2–4). Six patients (46%) had a prior auto-HCT, and 7 (54%) had a hematopoietic stem cell comorbidity index (HCT-CI) of >3. Median time from diagnosis to salvage auto-HCT was 58.3 (range 7.6-–132) months. Five patients (38%) had high-risk cytogenetic abnormalities (1q+ in all 5). Eight (61%) patients received melphalan alone, 4 (31%) received busulfan/melphalan, and 1 (8%) received gemcitabine/busulfan/melphalan/panobinostat as their conditioning regimen (Table 1). Three patients (23%) started maintenance with dara alone, while the remaining 10 (77%) patients received dara + pom. At study entry, 6 patients (46%) were in complete response (CR), 4 (31%) in very good partial response (VGPR), 2 (15%) in partial response (PR), and 1 (8%) had stable disease (SD). At day 100 post maintenance, 9 (69%) were in CR, while 1 (8%) each had VGPR, PR, SD and progressive disease (PD), respectively. For the 12 patients that did not progress at day 100, best response to dara +/- pom maintenance was CR in 10 (83%), and VGPR and SD in 1 (8%) each. With a median follow up of 20.6 months (range: 5.7–43.9) from the start of maintenance, 3 patients had progressed but there are no deaths so far. Median PFS from the date of auto-HCT was 31.9 (31.1-NA) months, and from start of maintenance 28.5 (95% CI 26.3-NA) months. 2-year PFS was 92% (Figure 1). Most common adverse events were neutropenia (n=11, 84%; none grade>3), bacterial infection (n=6, 46%; none grade >3), and grade 1-2 diarrhea, grade 1-2 fatigue, grade 1 thrombocytopenia (n=5, 38% each). Summary/Conclusion: Maintenance therapy with dara, with or without pom, is safe and feasible after a salvage auto-HCT for MM, with 83% achieving a CR. After a median follow up of 2 years, the median PFS was 28.5 months. The trial was terminated due to poor accrual.Keywords: Autologous hematopoietic stem cell transplantation, Maintenance, Multiple myeloma, Stem cell transplant" @default.
• W4385702500 created "2023-08-10" @default.
• W4385702500 creator A5001970750 @default.
• W4385702500 creator A5008785159 @default.
• W4385702500 creator A5012809293 @default.
• W4385702500 creator A5015342719 @default.
• W4385702500 creator A5016260142 @default.
• W4385702500 creator A5017057018 @default.
• W4385702500 creator A5022871468 @default.
• W4385702500 creator A5029237145 @default.
• W4385702500 creator A5032868562 @default.
• W4385702500 creator A5037077714 @default.
• W4385702500 creator A5037963602 @default.
• W4385702500 creator A5038235561 @default.
• W4385702500 creator A5038619722 @default.
• W4385702500 creator A5048362577 @default.
• W4385702500 creator A5048913229 @default.
• W4385702500 creator A5050962913 @default.
• W4385702500 creator A5052310700 @default.
• W4385702500 creator A5055404021 @default.
• W4385702500 creator A5055885795 @default.
• W4385702500 creator A5055929208 @default.
• W4385702500 creator A5060313982 @default.
• W4385702500 creator A5066894053 @default.
• W4385702500 creator A5068834306 @default.
• W4385702500 creator A5071516639 @default.
• W4385702500 date "2023-08-01" @default.
• W4385702500 modified "2023-09-27" @default.
• W4385702500 title "P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION" @default.
• W4385702500 doi "https://doi.org/10.1097/01.hs9.0000972100.00274.8c" @default.
• W4385702500 hasPublicationYear "2023" @default.
• W4385702500 type Work @default.
• W4385702500 citedByCount "0" @default.
• W4385702500 crossrefType "journal-article" @default.
• W4385702500 hasAuthorship W4385702500A5001970750 @default.
• W4385702500 hasAuthorship W4385702500A5008785159 @default.
• W4385702500 hasAuthorship W4385702500A5012809293 @default.
• W4385702500 hasAuthorship W4385702500A5015342719 @default.
• W4385702500 hasAuthorship W4385702500A5016260142 @default.
• W4385702500 hasAuthorship W4385702500A5017057018 @default.
• W4385702500 hasAuthorship W4385702500A5022871468 @default.
• W4385702500 hasAuthorship W4385702500A5029237145 @default.
• W4385702500 hasAuthorship W4385702500A5032868562 @default.
• W4385702500 hasAuthorship W4385702500A5037077714 @default.
• W4385702500 hasAuthorship W4385702500A5037963602 @default.
• W4385702500 hasAuthorship W4385702500A5038235561 @default.
• W4385702500 hasAuthorship W4385702500A5038619722 @default.
• W4385702500 hasAuthorship W4385702500A5048362577 @default.
• W4385702500 hasAuthorship W4385702500A5048913229 @default.
• W4385702500 hasAuthorship W4385702500A5050962913 @default.
• W4385702500 hasAuthorship W4385702500A5052310700 @default.
• W4385702500 hasAuthorship W4385702500A5055404021 @default.
• W4385702500 hasAuthorship W4385702500A5055885795 @default.
• W4385702500 hasAuthorship W4385702500A5055929208 @default.
• W4385702500 hasAuthorship W4385702500A5060313982 @default.
• W4385702500 hasAuthorship W4385702500A5066894053 @default.
• W4385702500 hasAuthorship W4385702500A5068834306 @default.
• W4385702500 hasAuthorship W4385702500A5071516639 @default.
• W4385702500 hasBestOaLocation W43857025001 @default.
• W4385702500 hasConcept C126322002 @default.
• W4385702500 hasConcept C141071460 @default.
• W4385702500 hasConcept C143998085 @default.
• W4385702500 hasConcept C2776063141 @default.
• W4385702500 hasConcept C2776364478 @default.
• W4385702500 hasConcept C2776694085 @default.
• W4385702500 hasConcept C2777408962 @default.
• W4385702500 hasConcept C2778524551 @default.
• W4385702500 hasConcept C2779050716 @default.
• W4385702500 hasConcept C2779823535 @default.
• W4385702500 hasConcept C2780007613 @default.
• W4385702500 hasConcept C2780775027 @default.
• W4385702500 hasConcept C2781119759 @default.
• W4385702500 hasConcept C2911091166 @default.
• W4385702500 hasConcept C535046627 @default.
• W4385702500 hasConcept C71924100 @default.
• W4385702500 hasConceptScore W4385702500C126322002 @default.
• W4385702500 hasConceptScore W4385702500C141071460 @default.
• W4385702500 hasConceptScore W4385702500C143998085 @default.
• W4385702500 hasConceptScore W4385702500C2776063141 @default.
• W4385702500 hasConceptScore W4385702500C2776364478 @default.
• W4385702500 hasConceptScore W4385702500C2776694085 @default.
• W4385702500 hasConceptScore W4385702500C2777408962 @default.
• W4385702500 hasConceptScore W4385702500C2778524551 @default.
• W4385702500 hasConceptScore W4385702500C2779050716 @default.
• W4385702500 hasConceptScore W4385702500C2779823535 @default.
• W4385702500 hasConceptScore W4385702500C2780007613 @default.
• W4385702500 hasConceptScore W4385702500C2780775027 @default.
• W4385702500 hasConceptScore W4385702500C2781119759 @default.
• W4385702500 hasConceptScore W4385702500C2911091166 @default.
• W4385702500 hasConceptScore W4385702500C535046627 @default.
• W4385702500 hasConceptScore W4385702500C71924100 @default.
• W4385702500 hasIssue "S3" @default.
• W4385702500 hasLocation W43857025001 @default.
• W4385702500 hasLocation W43857025002 @default.
• W4385702500 hasOpenAccess W4385702500 @default.
• W4385702500 hasPrimaryLocation W43857025001 @default.
• W4385702500 hasRelatedWork W1197848312 @default.
• W4385702500 hasRelatedWork W2478188943 @default.

• next